Oritavancin compared against vancomycin for skin infections

09/10/2013 | SkinAndAllergyNews.com

The effectiveness of single-dose intravenous oritavancin was similar to that of seven- to 10-day treatment with intravenous vancomycin for acute bacterial skin and skin structure infections, a multicenter study found. The most common adverse events reported in the oritavancin group included nausea, diarrhea and headache. Oritavancin was "well-tolerated, with a safety profile similar to vancomycin," lead author Dr. G. Ralph Corey reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy.

View Full Article in:

SkinAndAllergyNews.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC